BRPI9914571A - composto, processo para sua preparação, uso do mesmo, bem como composição farmacêutica. - Google Patents

composto, processo para sua preparação, uso do mesmo, bem como composição farmacêutica.

Info

Publication number
BRPI9914571A
BRPI9914571A BRPI9914571A BRPI9914571A BRPI9914571A BR PI9914571 A BRPI9914571 A BR PI9914571A BR PI9914571 A BRPI9914571 A BR PI9914571A BR PI9914571 A BRPI9914571 A BR PI9914571A BR PI9914571 A BRPI9914571 A BR PI9914571A
Authority
BR
Brazil
Prior art keywords
alkyl
aryl
compound
preparation
well
Prior art date
Application number
BRPI9914571A
Other languages
English (en)
Inventor
Carmen Almansa
Concepcion Gonzalez
M Carmen Torres
Original Assignee
Uriach & Cia Sa J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uriach & Cia Sa J filed Critical Uriach & Cia Sa J
Publication of BRPI9914571A publication Critical patent/BRPI9914571A/pt
Publication of BRPI9914571B1 publication Critical patent/BRPI9914571B1/pt
Publication of BRPI9914571B8 publication Critical patent/BRPI9914571B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91—Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

patente de invenção: "imidazóis com atividade antiinflamatória". compostos de fórmula i, na qual: um de x ou y representa n e o outro representa c; r~ 1~ representa hidrogênio, metila, halogênio, ciano, nitro, -cho, -coch~ 3~ ou -coor~ 4~; r~ 2~ representa arila ou heteroarila opcionalmente substituída; r~ 3~ representa c~ 1-8~ alquila, c~ 1-8~ haloalquila ou -nr~ 4~r~ 6~; r~ 4~ representa hidrogênio, c~ 1-8~ alquila ou arila c~ 0-8~ alquila; r~ 8~ representa hidrogênio, c~ 1-8~ alquila, arila c~ 1-8~ alquila, -cor~ 8~ ou -coor~ 8~; r~ 8~ representa c~ 1-8~ alquila ou c~ 1-8~ haloalquila; a arila, nas definições acima, representa a fenila ou a naftila; e a heteroarila, nas definições acima, representa a piridina, a pirazina, a pirimidina ou a piridazina, que pode ser opcionalmente fundida a um anel de benzeno. estes compostos são úteis como inibidores da ciclooxigenase-2.
BRPI9914571 1998-10-16 1999-10-15 composto, processo para sua preparação, uso do mesmo, bem como composição farmacêutica. BRPI9914571B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES9802222 1998-10-16
PCT/ES1999/000327 WO2000023426A1 (es) 1998-10-16 1999-10-15 Nuevos imidazoles con actividad antiinflamatoria

Publications (3)

Publication Number Publication Date
BRPI9914571A true BRPI9914571A (pt) 2001-11-06
BRPI9914571B1 BRPI9914571B1 (pt) 2011-10-18
BRPI9914571B8 BRPI9914571B8 (pt) 2021-07-06

Family

ID=8305557

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI9914571 BRPI9914571B8 (pt) 1998-10-16 1999-10-15 composto, processo para sua preparação, uso do mesmo, bem como composição farmacêutica.
BR9914571-5A BR9914571A (pt) 1998-10-16 1999-10-15 Imidazóis com atividade antiinflamatória

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR9914571-5A BR9914571A (pt) 1998-10-16 1999-10-15 Imidazóis com atividade antiinflamatória

Country Status (20)

Country Link
US (1) US6838476B1 (pt)
EP (1) EP1122243B1 (pt)
JP (1) JP4480894B2 (pt)
KR (2) KR100715918B1 (pt)
AR (1) AR024222A1 (pt)
AT (1) ATE275549T1 (pt)
AU (1) AU6204899A (pt)
BE (1) BE2011C024I2 (pt)
BR (2) BRPI9914571B8 (pt)
CA (1) CA2346847C (pt)
CY (1) CY2011009I2 (pt)
DE (2) DE122011100028I1 (pt)
DK (1) DK1122243T3 (pt)
ES (1) ES2228109T3 (pt)
FR (1) FR11C0028I2 (pt)
HK (1) HK1039331B (pt)
LU (1) LU91849I2 (pt)
NO (2) NO319074B1 (pt)
PT (1) PT1122243E (pt)
WO (1) WO2000023426A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2159489B1 (es) * 2000-03-23 2002-04-16 Uriach & Cia Sa J Nuevos derivados de imidazol con actividad antiinflamatoria.
ES2166710B1 (es) * 2000-04-25 2004-10-16 J. URIACH & CIA, S.A. Nuevos compuestos heterociclicos con actividad antiinflamatoria.
ES2184633B1 (es) * 2001-08-07 2004-08-01 J. URIACH & CIA, S.A. Procedimiento para la preparacion de derivados de 4-(imidazol-1-il) bencenosulfonamida.
EP1494667A1 (en) 2002-04-12 2005-01-12 Pfizer Japan Inc. Imidazole compounds as anti-inflammatory and analgesic agents
KR100804827B1 (ko) * 2002-05-17 2008-02-20 씨제이제일제당 (주) 티아졸리딘-4-온 유도체, 그 제조방법 및 약제학적 조성물
ATE548354T1 (de) * 2002-07-24 2012-03-15 Ptc Therapeutics Inc Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
ES2215474B1 (es) 2002-12-24 2005-12-16 J. URIACH & CIA S.A. Nuevos derivados de fosforamida.
FR2881049B1 (fr) * 2005-01-24 2008-12-26 Vetoquinol Sa Sa Medicament destine a etre administre par voie orale comprenant un inhibiteur de la cyclo-oxygenase-2, et son procede de preparation
WO2009005675A1 (en) 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
GB0806745D0 (en) * 2008-04-14 2008-05-14 Syngenta Participations Ag Novel imidazole derivatives
WO2010068794A2 (en) 2008-12-10 2010-06-17 The General Hospital Corporation Hif inhibitors and use thereof
US20110045101A1 (en) * 2009-05-06 2011-02-24 E.I. Du Pont De Nemours And Company Fungicidal substituted azoles
CN102464652B (zh) 2010-11-02 2013-08-28 北京欧博方医药科技有限公司 咪唑衍生物、制备方法及用途
CA3209491A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3901908A (en) * 1970-12-28 1975-08-26 Ciba Geigy Corp 2-alkyl- and 2-cycloalkyl-4,5-bis-phenyl-imidazoles
IT1168008B (it) * 1981-07-31 1987-05-20 Zambon Spa Imidazol-eteri ed ester, procedimenti per prepararli e composizioni farmaceutiche che li contengono
US4576958A (en) * 1984-01-23 1986-03-18 E. I. Du Pont De Nemours And Company Antihypertensive 4,5-diaryl-1H-imidazole-2-methanol derivatives
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
EP1288206B1 (en) * 1996-04-12 2008-09-17 G.D. Searle LLC Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors

Also Published As

Publication number Publication date
AR024222A1 (es) 2002-09-25
CA2346847C (en) 2009-12-22
DE122011100028I1 (de) 2011-12-08
HK1039331B (zh) 2005-01-07
BR9914571A (pt) 2001-11-06
CY2011009I1 (el) 2014-04-09
NO2011012I2 (no) 2013-05-06
BRPI9914571B1 (pt) 2011-10-18
ES2228109T3 (es) 2005-04-01
NO319074B1 (no) 2005-06-13
JP2002527508A (ja) 2002-08-27
EP1122243A1 (en) 2001-08-08
BE2011C024I2 (pt) 2019-03-05
HK1039331A1 (en) 2002-04-19
ATE275549T1 (de) 2004-09-15
KR100808433B1 (ko) 2008-03-03
BRPI9914571B8 (pt) 2021-07-06
JP4480894B2 (ja) 2010-06-16
DE69920028D1 (de) 2004-10-14
US6838476B1 (en) 2005-01-04
KR20060129102A (ko) 2006-12-14
AU6204899A (en) 2000-05-08
PT1122243E (pt) 2004-12-31
DK1122243T3 (da) 2005-01-10
NO20011790L (no) 2001-06-14
EP1122243B1 (en) 2004-09-08
KR20010080186A (ko) 2001-08-22
DE69920028T2 (de) 2005-09-22
NO2011012I1 (no) 2011-08-08
FR11C0028I2 (fr) 2012-06-22
CA2346847A1 (en) 2000-04-27
CY2011009I2 (el) 2014-04-09
KR100715918B1 (ko) 2007-05-08
FR11C0028I1 (pt) 2011-09-23
LU91849I2 (fr) 2011-09-27
NO20011790D0 (no) 2001-04-09
WO2000023426A1 (es) 2000-04-27

Similar Documents

Publication Publication Date Title
BRPI9914571A (pt) composto, processo para sua preparação, uso do mesmo, bem como composição farmacêutica.
BR0211427A (pt) Compostos, processo para preparar os mesmos, composição adequada para combater fungos danosos, uso de compostos, e, processo para combater fungos danosos
BR9908764A (pt) Composto e seus sais farmaceuticamente aceitáveis ou ésteres hidrolisáveis in vivo, uso destes, processo para prepará-los, e, composição farmacêutica
ECSP034865A (es) Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas
EE9900217A (et) Sulfiinhappe derivaadid, nende valmistamine ja kasutamine
ES2043625T3 (es) Derivados de acido ariloxicarboxilico, su preparacion y empleo.
BR9914451A (pt) Composto de oxazol, processo para sua preparação, composição farmacêutica compreendendo dito composto, uso da composição e métodos de tratamento
BR9813022A (pt) Derivados de ésteres hidroxiacéticos, seu processo de preparação e sua utilização como intermediários de sìntese
AR032360A1 (es) Compuesto derivado de acido homoiminopiperidinil hexanoico, composicion farmaceutica que lo comprende y compuestos intermediarios que se usan en su preparacion
BR0003105A (pt) Compostos de beta-carbolina, processo para sua preparação e composições farmacêuticas contendo os mesmos
BR9910573A (pt) Compostos antipicornavirais, preparação e uso dos mesmos
BR9802804A (pt) Compostos benzimidazol, benzoxazol e benzotiazol, processo para sua preparação e composições farmacéuticas contendo os mesmos.
UY28528A1 (es) Nuevos compuestos
DK92781A (da) Fremgangsmaade til fremstilling af indanderivater eller syreadditionssalte deraf
DK0561948T3 (da) Phosphonsyrederivater, der kan anvendes som antiinflammatoriske midler
DK544588D0 (da) I 2-stillingen heterocyclisk substituerede 4-aryl-5-carbamoyl-6-methyl-1,4-dihydropyridin-3-carboxylsyre-forbindelser, deres anvendelse til fremstilling af et laegemiddel til behandling af allergiske og inflammatoriske tilstande og farmaceutiske praeparater indeholdende disse forbindelser samt 2-acyl-3-aryl-propensyreestere til anvendelse som udgangsmateriale ved deres fremstilling
AT389108B (de) Neue pyridazinonderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen
BRPI0403028A (pt) Compostos heterocìclicos de oxima, processo para sua preparação e composições farmacêuticas contendo os mesmos
DK164164C (da) 2,4-diphenyl-1,3-dioxanderivater og fremgangsmaade til fremstilling deraf samt farmaceutisk middel indeholdende derivaterne og disses anvendelse til fremstilling af det farmaceutiske middel
PT937043E (pt) Novos derivados tetra-hidropiridinicos substituidos processo para a sua preparacao e as composicoes farmaceuticas que os contem
DK1165485T3 (da) Fremgangsmåde til fremstilling af pesticidmellemprodukter
CO4940417A1 (es) DERIVADOS DE 2,3-DIHIDROFURO[3,2-b]PIRIDINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
BR9801448A (pt) Compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos.
AR029468A1 (es) Derivados de aminoacidos n-mercaptoacilados, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
BR9800763A (pt) Novos compostos 2-amino indano, um processo para sua preparação e composições farmacêuticas contendo os mesmos.